The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Frances A. Collichio
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Morphotek; Roche/Genentech
Thomas Amatruda
Other Remuneration - Amgen
Neil N. Senzer
No relevant relationships to disclose
Jason Chesney
Research Funding - Amgen
Keith A. Delman
No relevant relationships to disclose
Lynn E. Spitler
Consultant or Advisory Role - BioVex
Research Funding - Amgen; BioVex
Igor Puzanov
Honoraria - Amgen
Susan Doleman
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yining Ye
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ari M. Vanderwalde
Employment or Leadership Position - Amgen
Robert Coffin
Consultant or Advisory Role - Amgen
Howard Kaufman
Consultant or Advisory Role - Amgen
Research Funding - Amgen